Clin Cancer Res: Navu single anti-Ipi single anti-inflixi single anti/cytoju single anti-treatment melanoma

For patients with advanced melanoma, TNF blockers can be used to treat gastrointestinal inflammatory side effects after Narcosin and/or Ipi monoantigen therapy.
preclinical data show that anti-TNF can improve the efficacy of immuno-checkpoint inhibitors.
TICIMEL (NTC03293784) study is an open-label, two-arm Phase IB clinical trial that recruited 14 patients with advanced and/or metastatic melanoma (Phase IIIc/IV) to receive navuda (1 mg/kg) and Ipi monoanti (3 mg/kg) combined Invlixi monoanti (5 mg/kg, n=6) or cyto-bead monoanti (400/200 mg, n=8).
end point is safety, and the secondary endpoint is anti-tumor activity.
only one case of dose-limiting toxicity (DLT) was observed in the Invlixi monoantigen queue.
security of both different joint scenarios is good.
reactions associated with inflixi monoantigen therapy were less common than those associated with cytojumal monoantigen.
one patient was not included in the treatment response analysis in the Cyto-Pearl monoantial queue.
4 out of 8 patients showed liver and bile dysfunction, and 7 assessed patients were all given objective remission (OR), including 4 complete remission (CR) and 3 partial remission (PR).
in the Invlixi monoantigen queue, there were 1 case of CR and 2 cases of PR, and 3 patients with progression (PD).
the activation and maturation of systemic T-cell responses were observed in both groups of patients.
, the study showed that the two combined options were safe for patients with advanced melanoma and showed some clinical and biological activity.
rate of patients with seredoju single anti-queue deserves further study.
。